Hopkinson Craig C. 4

What Happened

• Craig C. Hopkinson, EVP R&D and Chief Medical Officer of Alkermes plc, reported exercising options and selling company stock on Feb 2, 2026. He exercised or converted 5,000 option-derived shares at $19.34 (cost $96,700) and reported a 5,000-share derivative disposition at $0.00 (transaction code M). He also sold 9,000 shares in open-market transactions (transaction code S) for a combined reported proceeds of $305,385 (5,000 shares at $34.24 for $171,225; 4,000 shares at $33.54 for $134,160).

Key Details

• Transaction date: 2026-02-02 (filing date: 2026-02-02 — appears timely)
• Option exercise (M): 5,000 shares acquired @ $19.34 = $96,700; plus a 5,000-share derivative disposition reported at $0.00
• Open-market sales (S): 5,000 shares @ $34.24 = $171,225 (weighted avg; shares sold across $33.67–$34.64) and 4,000 shares @ $33.54 = $134,160; total proceeds ≈ $305,385
• Shares owned after transaction: not provided in the excerpt of the filing
• Footnotes: Sales and the option exercise were executed pursuant to a Rule 10b5‑1 trading plan adopted by Hopkinson on 3/14/2025 (F1, F2). F3 notes the reported sale price is a weighted average across multiple trades; F4 confirms the options were fully vested.
• Transaction codes: M = exercise/conversion of a derivative (options); S = sale of securities

Context

• The filing shows same‑day option exercise(s) and open‑market sales. When options are exercised and shares are sold the same day, that pattern often reflects an exercise followed by immediate sale (commonly used to cover exercise costs or taxes), but the filing itself does not state the insider’s motivation.
• All reported actions were made under a pre-established 10b5‑1 trading plan, which structures and schedules trades in advance.